An analysis of discontinuation in randomized controlled trials for chronic obstructive pulmonary disease (COPD) has determined the main factors causing patients to drop out of clinical trials. The results were published in the International Journal of COPD.
An analysis of discontinuation in randomized controlled trials for chronic obstructive pulmonary disease (COPD) has determined the main factors causing patients to drop out of clinical trials. The results were published in the International Journal of COPD.
Researchers analyzed more than 2300 patients in 3 trials of 6- and 12-month duration comparing budesonide/formoterol and formoterol in moderate, severe, and very severe COPD. Typically, there is a high rate of discontinuation in randomized controlled trials for COPD, especially for patients with more severe disease.
“A particular problem arises when differential dropout between study arms occurs on top of evenly distributed random discontinuations,” the authors explained. “The net effect can lead to potential bias in favor of a weaker treatment, if the sicker people in that arm are lost during follow-up.”
They not only investigated the impact of disease severity and study duration on COPD exacerbations, but also sought to better understand the impact of premature discontinuations. One trial had been conducted in 237 sites in the United States, Europe, and Mexico. The second trial was conducted in 180 sites in the United States, Central and South America, and South Africa. The third trial was conducted at 194 sites in the United States, Czech Republic, the Netherlands, Poland, and South Africa.
The analysis found that exacerbation rates were higher with longer study duration and with formoterol more so than with budesonide/formoterol. With shorter study durations, there was a 40% to 47% reduction in the risk of first exacerbations between treatments.
Disease severity also influenced exacerbation outcomes. The severity of COPD had less of an impact in studies with shorter duration, but there was a significant difference in studies longer than 5 months. Treatment effect decreased from 41%-51% for shorter durations to just 29% for severe COPD and 22% for very severe COPD in studies that were 12 months long. Treatment difference in patients with moderate COPD was unaffected regardless of duration.
“Future studies of new agents designed to modify exacerbation outcomes in COPD may benefit from adopting a shorter focused design, which minimizes the effect of differential dropout, an approach already shown to be effective in clinical trials of COPD,” the authors concluded.
A Pulmonologist on Why You Should Think About Respiratory Health and the Lungs
November 16th 2021On this episode of Managed Care Cast, we speak with MeiLan K. Han, MD, MS, the author of a book released this month called Breathing Lessons: A Doctor’s Guide to Lung Health. Han, a pulmonologist, gives an inside tour of the lungs and how they work, zooms out to examine the drivers of poor respiratory health, and addresses policy changes that are needed to improve lung health.
Listen
Patient-Reported Outcomes Help to Uncover Frailty Patterns in Those With Acute COPD Exacerbations
April 22nd 2024Study findings demonstrate the pivotal role of patient-reported outcomes in identifying frailty among individuals experiencing acute exacerbations of chronic obstructive pulmonary disease (COPD).
Read More
Study: Decreased BMI Increases Severe Exacerbation, All-Cause Mortality Risk in Patients With COPD
April 10th 2024Decreased body mass index (BMI) in patients with chronic obstructive pulmonary disease (COPD) was linked to a higher risk of severe exacerbations and all-cause mortality, emphasizing the importance of monitoring BMI for managing COPD and predicting outcomes.
Read More
Study: 1 in 6 US Patients With COPD Suffers From Cost-Related Medication Nonadherence
April 3rd 2024Medication nonadherence among patients with chronic obstructive pulmonary disease (COPD) is associated with increasing COPD symptoms, hospitalizations, morbidity, mortality, and health care expenditures.
Read More